Pancreatic adenocarcinoma (PA) is the fourth leading cause of cancer-related death worldwide, with a poor 5-year survival rate of \<10% across all stages. PA represents 90% of pancreatic tumours; the other tumours are benign lesions with a pseudotumoral form of chronic pancreatitis or malignant forms such as an endocrine tumour, haematological malignancy or metastasis ([@bib21]). At presentation, ∼80% of patients with PA have a locally advanced or metastatic disease, and histological confirmation is usually required before palliative chemotherapy and/or radiotherapy. In this context, endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is considered a standard for PA confirmation in patients presenting an isolated pancreatic tumour ([@bib1]), with a sensitivity and specificity ranging from 78 to 95% and from 75 to 100%, respectively ([@bib45]). The procedure needs to be repeated in ∼20--30% of cases, leading to a potential delay for diagnostic confirmation ([@bib38]).

To date, the carbohydrate antigen CA19.9 (CA19.9), which has been approved by the FDA for PA management, is the only marker used in daily practice. Its clinical interest has been intensively studied, and it has a sensitivity of 70--81% for PA diagnosis ([@bib8]; [@bib36]). The well-known limitation of CA19.9 is its low specificity due to the presence of elevated levels in non-malignant situations, such as cholestasis or diabetes mellitus. In this context, a liquid biopsy based on circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs), which result from metastatic or primary tumour release, are considered very promising to optimise the diagnosis and decision making in PA patients. CTCs are rare cells that disseminate into the bloodstream, and their detection is usually performed by a combination of enrichment and detection methods. Cell-free DNA (cfDNA) corresponds to all DNA fragments resulting from both normal and tumour cells, whereas ctDNA harbors specific genetic alterations from tumour cells ([@bib10]). The detection of ctDNA requires ultrasensitive technologies, including next-generation sequencing-based or digital PCR-based platforms with a sensitivity up to 0.01% of the allelic frequency and a detection rate ranging from 26 to 90% in PA ([@bib4]; [@bib11]; [@bib23]; [@bib30]; [@bib39]; [@bib46]; [@bib7]).

To date, the usefulness of CTC and ctDNA detection has not been clearly established in PA patients. We previously reported that CTC detection using the Screencell method had a sensitivity and specificity of 55% and 100%, respectively, for PA diagnosis ([@bib19]). Similar to colorectal cancer, the ctDNA level seems to be associated with the disease stage and may have potential prognostic impacts in patients presenting with a PA ([@bib11]; [@bib23]; [@bib30]; [@bib39]).

To the best of our knowledge, the diagnostic value of CA19.9 compared with CTC and circulating DNA, as well as their combination, has never been evaluated in PA patients. We conducted a study to investigate their relevance alone or in combination in patients who underwent EUS-FNA for a pancreatic solid tumour.

Materials and methods
=====================

Patients and sample collection
------------------------------

Patients undergoing EUS-FNA for the exploration of a solid pancreatic tumour in Rouen University Hospital from January 2011 to March 2014 were included after their informed consent. No patients had received treatment before the EUS-FNA. PA was classified as localised disease (LD), locally advanced disease (LAD) or metastatic disease (MD) based on a CT-scan. For each patient, blood samples were collected into a single EDTA tube (4 ml) for CTC analysis and one heparinised tube (4 ml) for CA19.9 and circulating DNA (cDNA) analysis immediately before the EUS-FNA procedure. The CA19.9, CTC and cDNA analyses were centralised, and the study was approved by the institutional review board (Northwest I).

EUS-FNA technique
-----------------

The EUS-FNA procedures were performed under general anesthesia by three experimented endoscopists. The echoendoscopic examination was performed with radial (GF-UE160-AL5, Olympus, Tokyo, Japan) and/or linear (GF-UC140P-AL5, Olympus, Tokyo, Japan) echoendoscopes, and cytological samples were obtained using three back-and-forth passages with 22 G needles. The samples was placed in Hank\'s solution, fixed in AFA (absolute alcohol: 50%, 40% formaldehyde: 20%, acetic acid: 5%, and distilled water: 25%) and embedded in paraffin. The slides were stained with hematoxylin-eosin-safran and analysed by a pathologist who classified the samples as follows: positive for malignancy, suspicious for malignancy, negative for malignancy or benign lesion and non-contributive. In cases of non-contributive FNA, the histological confirmation was obtained using a second FNA, biopsy or a surgical procedure according to the clinical context.

Determination of the *KRAS* mutational status in tumour tissue
--------------------------------------------------------------

DNA for the *KRAS* mutational status determination was based on the most adequate genetic material when available (surgical specimen\>biopsy\>paraffin-embedded section of the cell blocks obtained from the EUS-FNA). After extraction, genotyping of *KRAS* mutations within exon 2 (codons 12 and 13) was performed using the SNaPshot multiplex assay, which required at least 5% tumour cells, as previously described ([@bib26]).

CA 19.9 analysis
----------------

CA19.9 was measured on a Kryptor PLC (B.R.A.H.M.S., Hennigsdorf, Germany) by the immunological method in the homogeneous phase. The upper limit of the normal value was 35 UI ml^−1^.

Circulating total DNA
---------------------

cDNA analysis was performed after centrifuging the peripheral blood samples at 2700 g for 20 min at room temperature and then at 16 000 g for 10 min at 4 °C. The second step was performed before extraction and after the heparinised plasma sample previously collected for CA19.9 analysis was thawed. DNA was extracted from 0.35 to 1.7 ml of heparinised plasma using the QIamp Circulating Nucleic Acid kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Data regarding the influence of the initial plasma volume on cDNA analysis are shown in [Supplementary Figures 1--4](#sup1){ref-type="supplementary-material"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The sample was eluted in a final volume of 30 *μ*l and stored at −20 °C. Quantification of the cfDNA was performed using a fluorometric method as previously described ([@bib31], [@bib32]). The concentration was expressed as ng ml^−1^ of plasma using the following equation: CP=CExVE/VP, where CE corresponds to the concentration of extracted cfDNA (ng *μ*l^−1^), CP corresponds to the concentration of cfDNA in the plasma (ng ml^−1^), VE corresponds to the elution volume used for the cfDNA extraction (*μ*l) and VP corresponds to the plasma volume used to extract the cfDNA (ml). Consequently, the cfDNA concentrations could be compared between the patients.

Circulating tumour DNA
----------------------

The detection of ctDNA was based on *KRAS* mutations. First, preamplification was performed since this step was not associated with any qualitative and quantitative alterations (including mutant allelic fraction) in the dPCR results compared with those obtained from the original sample ([@bib43]; [@bib20]) ([Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). Thus, a preamplification using four ng of cfDNA was performed in a final volume of 25 *μ*l consisting of 12.5 *μ*l of 2X TaqMan genotyping master mix (Applied Biosystems, Foster City, CA, USA), 0.25 *μ*l of the primer/probe mixture (Custom TaqMan SNP Genotyping Assays for c.35G\>A detection, Life Technologies, Carlsbad, CA, USA) and 2 *μ*l of heparinase (New England Biolabs, Ipswich, MA, USA). According to the results of previous runs showing an inhibitory effect of heparin on preamplification, heparinase was systematically added to inhibit the action of heparin in the PCR ([@bib5]). All runs were performed using the following thermocycling conditions: 10 min at 95 °C, followed by 15 cycles of 15 s at 95 °C and 4 min at 60 °C. The droplet-based dPCR (ddPCR) platform (Qx200 ddPCR system, Bio-Rad, Hercules, CA, USA) was used for ctDNA detection. A multiplex assay (Bio-Rad, Hercules, CA, USA) was used to screen the most common *KRAS* mutations found in PA (*n*=7: c.34G\>A, c.34G\>C, c.34G\>T, c.35G\>A, c.35G\>C, c.35G\>T and c.38G\>A). A simplex assay (Life Technologies, Carlsbad, CA, USA) based on specific *KRAS* mutations was also performed to confirm the results of positive samples obtained using the multiplex assay. The ddPCR conditions and precisions concerning the limit of detection are described in [Supplementary Materials](#sup1){ref-type="supplementary-material"}. Two simplex assays (c.34G\>A and c.34G\>C) failed because no amplification could be achieved for DNA from heparinised plasma. The ddPCR analysis was performed blindly from clinical data.

Circulating tumour cell analysis
--------------------------------

Blood samples were conserved at room temperature and processed within 3 h of collection. CTC isolation was performed using the size-based Screencell Cyto filtration device according to manufacturer's instructions as previously reported ([@bib19]; [@bib24]). Briefly, 4 ml of the ScreenCell FC filtration buffer was incubated for 8 min with 3 ml of blood to fix the target cells and lyse the red blood cells (RBCs). Then, the mixture was drawn through the filter by a vacuum tube. Following the filtration of the fixed cells, an additional 1.6 ml of 1 × phosphate-buffered saline was filtered to remove debris from the filter. Cell cytology was visualised with hematoxylin-eosin-safran staining. Enumeration and analysis of the structural characterisation of the CTCs was performed by an experienced cytopathologist blinded to the histological diagnosis. The cells were classified as 'positive' or 'negative' for CTC based on cytomorphological features. The cells were considered positive (i.e., circulating tumour cells) by the presence of at least four of the following criteria as previously described ([@bib18]): anisonucleosis (ratio\>0.5), nuclei larger than the calibrated pore size of the membrane (8 *μ*m), irregular nuclei, high nucleo-cytoplasmic ratio, and presence of three-dimensional sheets ([Supplementary Figure 6](#sup1){ref-type="supplementary-material"}). Cells were considered negative (i.e., circulating non-tumour cells) by the absence of at least four criteria.

Statistical analysis
--------------------

The sensitivity, specificity, and negative and positive predictive values for the PA diagnosis were evaluated for EUS-FNA, which was considered the standard method, and for each marker. The performance of combinations, based on at least two positive markers among CA19.9, CTCs and ctDNA, was also analysed. A CA19.9 value above the normal limit and/or CTC⩾1 and/or detectable ctDNA based on the circulating multiplex *KRAS* analysis were the cut-offs used for the analysis of the combinations.

The prognostic impact was analysed for overall survival (OS) in PA patients. For the purpose of the study, the diagnosis of malignant tumours (i.e., PA or other malignant tumours) was defined either by histological evidence obtained by EUS-FNA and/or surgical specimens or by clinical outcomes with metastatic evolution and the CA19.9 serum level rather than 10-fold the normal value for PA. Benign lesions (i.e., chronic pancreatitis) were determined by follow-up of \>3 years without any evidence of progression and EUS-FNA classification of the sample as indeterminate or negative in at least one procedure. The OS was calculated from the time of EUS-FNA to death from any cause. Patients were followed until April 30, 2016. The characteristics of patients and between predefined groups were expressed as percentages or means±s.d. for continuous variables and were compared using the Chi-square test, Fisher\'s exact test and Student's *T* test as appropriate. Survival curves were calculated using the Kaplan--Meier method and compared with the log-rank test. The statistical analyses were calculated using StatView version 5.0 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Patient characteristics
-----------------------

A total of 68 patients presenting with a solid pancreatic tumour were included; their characteristics are listed in [Table 1](#tbl1){ref-type="table"}. The diagnosis corresponded to 58 (85%) malignant tumours (52 PA and 6 other malignant tumours) and 10 (15%) benign lesions ([Table 1](#tbl1){ref-type="table"}). For the 52 patients with PA, 13 had a LD, 17 had a LAD and the 22 remaining patients had a MD. Surgical resection of the tumour was performed in 9 patients, including 5 with PA, 3 with others malignant tumours (1 pancreatic neuroendocrine tumour (PanNET), 1 renal clear cell carcinoma metastasis and 1 fibrolamellar hepatocellular carcinoma with pancreas invasion) and 1 with a benign tumour corresponding to a pseudo-papillary tumour of the pancreas. The follow-up period was 25 months for all patients (April 2016) after the last patient was included (March 2014). At the time of the analysis, the median follow-up was 7.5 months (range 1--64), and 52 (76.5%) deaths were observed.

EUS-FNA results
---------------

A total of 86 EUS-FNA procedures were performed, including 1 procedure for 52 patients, 2 for 14 patients and 3 for 2 patients (mean=1.3±0.5). The diagnostic accuracy of the first EUS-FNA for PA was 76%, corresponding to a sensitivity and specificity of 73% and 88%, respectively ([Table 2](#tbl2){ref-type="table"}). The final diagnosis was based on EUS-FNA for 50 patients (first EUS-FNA, *n*=39; second or third EUS-FNA, *n*=11), a hepatic or surgical biopsy for 6 patients, surgical specimens for 9 patients and clinical outcomes with the CA19.9 level rather than 10-fold the normal value for the 3 remaining cases. There were two false positive results for PA, corresponding to one PanNET and one renal clear cell carcinoma metastasis on a surgical specimen.

CA19.9
------

CA 19.9 measurements were available for 63/68 (92.6%) patients, with a median value of 90 UI ml^−1^ (range 4--181 761) in all patients and 174 UI ml^−1^ (range 4--181 761) in PA. The mean CA19.9 concentration was not significantly different in patients with or without cholestasis (3087±9059 and 3587 ±12 935, respectively, *P*=0.92). The mean concentrations were 7435±28 102, 24±35, and 20±11 in PA, other malignant tumours and benign lesions, respectively (*P*=0.25). The difference between the mean and median values was due to the skewed distribution of the CA19.9 values, with 5 patients presenting CA19.9 values greater than 10 000 UI/ml (13 759; 16 490; 45 106; 64 095 and 181 761 UI ml^−1^) in PA group; conversely, the maximum CA19.9 in the other groups did not exceed 94 UI ml^−1^. The CA19.9 level was greater than the normal value in 79% (38/48) of the patients with PA malignant tumours, 17% (1/6) of the patients with non-PA malignant tumours and 0% (0/9) of the patients with benign lesions (*P*\<0.001). The sensitivity and specificity of CA19.9 for the PA diagnosis were 79% and 93%, respectively ([Table 2](#tbl2){ref-type="table"}).

According to the liver test, the sensitivity and specificity were superior for PA diagnosis in patients without cholestasis (81% and 100%, respectively) *vs* those with cholestasis (74% and 67%, respectively) ([Supplementary Tables 2 and 3](#sup1){ref-type="supplementary-material"}). There was no correlation between the median CA19.9 (⩾174 UI/ml) and the baseline clinical parameters.

CTC detection
-------------

The analysis was informative for 64/68 samples (94%), with filtration difficulties for the 4 remaining cases. CTCs were detected (⩾1 CTC ml^−1^) in 36/64 samples (56% of the study population) compared with 33/49 (67%) patients with PA. The median CTC levels were 1 CTC ml^−1^(range 0--151) *vs* 4 CTC ml^−1^ (range 0--151) in these two groups, respectively. As shown in [Table 2](#tbl2){ref-type="table"}, the sensitivity and specificity for the PA diagnosis were 67% and 80%, respectively. There was a trend for increased CTC detection with tumour stage, with positive CTC detected in 16/28 (57%) patients with LD/LAD *vs* 17/21 (81%) patients with MD (*P*=0.12) ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). There was no correlation between the presence of CTC or the median CTC (⩾4 CTC ml^−1^) and the baseline clinical parameters. There were three false positive PA results, corresponding to one PanNET and two benign lesions.

Total and tumour circulating DNA analyses
-----------------------------------------

Quantification of cfDNA was expressed as ng ml^−1^ of plasma and was successfully performed in 56 (82%) patients, with a median value of 57.6 ng ml^−1^ (range 12.9--925.3) in all patients and 59.5 ng ml^−1^ (range 12.9--925.3) in PA. The mean cfDNA concentrations were 99.2±137.2 ng ml^−1^ and 59.1±28.4 ng ml^−1^ in patients with malignant tumours (PA and others) and benign lesions, respectively (*P*=0.42). The mean cfDNA concentration was not significantly different according to the PA stage, with 73.8±45.6, 77.2±41.1 and 122.4±44 in the localised, locally advanced and metastatic diseases, respectively.

A *KRAS* circulating mutation was detected in 31/55 (56%) cases with available blood samples, corresponding to a ctDNA median value of 0.6% allelic frequency (range 0.17--41.1%) in all patients and 0.75% allelic frequency (range 0.33--41.1%) in PA. The sensitivity and specificity of ctDNA for the PA diagnosis were 65% and 75%, respectively ([Table 2](#tbl2){ref-type="table"}). There were 3 false positive PA results, corresponding to 1 PanNET and 2 benign lesions. There was a significant increase in ctDNA detection associated with tumour stage, with ctDNA present in 10/23 (43%) patients with LD/LAD *vs* 18/20 (90%) patients with MD (*P*=0.002) ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). Among the 27 PA patients with available paired plasma and tumour tissue samples, a *KRAS* mutation was found in 17/27 (63%) plasma samples. The concordance of the *KRAS* mutational status between the tissue and plasma was 19/27 (70.4%) ([Table 3](#tbl3){ref-type="table"}). For the three patients with a *KRAS* mutation in circulation and a wild-type *KRAS* status in the tumour tissue, re-examination of the blade used for determine the *KRAS* status in the tumour tissue showed low tumoural cellularity (i.e., \<20%). For the 31 plasma samples in which a *KRAS* mutation was identified with the multiplex assay, 23 (74%) were positive using the simplex assays ([Supplementary Table 5](#sup1){ref-type="supplementary-material"}) with the following mutational profiles: c.34G\>T (*n*=1), c.35G\>A (*n*=13), c.35G\>T (*n*=7), and c.38G\>A (*n*=6). The multiplex and simplex assay results were significantly correlated ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). There was no correlation between the cfDNA median (⩾59.5 ng ml^−1^) and the baseline clinical parameters. However, the presence of ctDNA was significantly associated with a larger primary tumour size (83% for tumours ⩾30 mm *vs* 42% for tumours \<30 mm, *P*=0.01).

Marker combinations
-------------------

The combined analysis of three markers was available in 51 (75%) patients, and 32 (63%) had at least two positive markers. The sensitivity and specificity for the PA diagnosis of the combinations were 78% and 91%, respectively ([Table 2](#tbl2){ref-type="table"}). The sensitivity was similar in patients with and without cholestasis (78% and 79%, respectively), whereas the specificity was superior in patients with cholestasis (100% *vs* 86%, respectively).

Circulating markers and outcomes
--------------------------------

The median OS in patients with PA was 5.6 months (range 0.1--61.9). The median OS was 11.1 months in patients with LD compared with 7.4 months and 2.6 months in patients with LAD and MD, respectively (*P*=0.006). Patients with PA and detectable ctDNA had a significantly shorter OS compared with patients without detectable ctDNA (5.2 months *vs* 11 months, respectively, *P*=0.01) ([Figure 3](#fig3){ref-type="fig"}). A high ctDNA value (above *vs* below the median) in PA patients was also significantly associated with a poorer outcome, with a median OS of 3.9 months *vs* 7.8 months, respectively (*P*= 0.04) ([Figure 3](#fig3){ref-type="fig"}). The ctDNA analysis showed a decrease in the OS by quartile repartition (\>75%, 50--75%, 25--50%, and \<25%), with a median OS of 2.4 months, 6.1 months, 7.4 months and 11 months, respectively (*P*=0.0004). There was no correlation between the other markers and the outcome in patients with PA and other lesions ([Figure 3](#fig3){ref-type="fig"}).

Discussion
==========

Our results suggest that CA19.9 alone and in combination with ctDNA and CTC analyses may represent a simple and efficient approach for PA diagnosis in patients presenting with SPTs with a sensitivity and specificity of their combination in the whole population of 78% and 91%, *vs* 73% and 88% for EUS-FNA alone, respectively. Moreover, considering the sample size for the subgroup analysis, CA19.9 performance decreased in cases of cholestasis, whereas the combination of markers remained relevant, despite the liver test. Moreover, we observed that a high ctDNA level at presentation may be associated with shorter survival in these patients. To the best of our knowledge, these markers have never been investigated together in patients undergoing an EUS-FNA for a solid pancreatic tumour. Because EUS-FNA may have some limitations, such as the need for general anesthesia, our results indicate that the analysis of these markers may provide relevant information for both diagnosis and prognosis.

*KRAS* mutations were logically used as targets for ctDNA detection because *KRAS* is the most commonly mutated gene in PA (90%), with a hotspot region (codons 12/13) covering 90% of *KRAS* mutations ([@bib14]). On the basis of a multiplex assay covering seven mutations in the hotspot region, we found a detection rate of 65% in PA patients, with an overall concordance of 70.4% in the subgroup with available paired tissue and blood samples. The ddPCR method developed in the present study showed a detection rate that was slightly superior to the rate that was recently reported (26--63%) ([@bib11]; [@bib23]; [@bib39]). In our work, a preamplification step was performed to improve mutant fragment DNA recovery ([@bib20]). Moreover, several clinical parameters, such as disease stage and prior treatment ([@bib11]), may be associated with ctDNA detection ([@bib4]; [@bib39]). In the present study, approximately 75% of the cases had advanced PA, although all patients were treatment naïve at the time of analysis. Finally, the release of different *KRAS* subclones into the plasma ([@bib2]; [@bib42]; [@bib23]) due to tumour heterogeneity may also interfere with the ddPCR results, as indicated by our results in which duplicate or triplicate circulating mutations were detected in three cases. Taken together, these findings emphasised that ctDNA appeared to be an important marker in PA patients and that biological, clinical and preanalytical conditions are key factors involved in its detection. On the basis of its prognostic impact in our series and in other studies ([@bib23]; [@bib30]; [@bib33]; [@bib39]; [@bib16]), further prospective studies are needed to determine the most appropriate conditions for ctDNA detection as well as its clinical impact in PA patients.

We detected CTCs in 56% of PA patients, which was concordant with previous reports using size-based enrichment methods ([@bib22]; [@bib24]; [@bib29]). The performance of CTC detection may be variable across techniques, with lower results obtained with immunological capture methods such as the Cellsearch technology([@bib25]; [@bib22]; [@bib6]), probably due to the small fraction of CTCs that express epithelial markers, such as EpCAM, in PA ([@bib15]). As shown by studies based on sized-based enrichment methods, we did not observe differences in survival between patients with positive CTC *vs* negative CTC results. To date, the prognostic value of CTC in PA patients remains a subject of debate. Indeed, although some studies using immunological capture ([@bib25]; [@bib6]) reported a decrease in survival in the presence of CTCs, a recent work suggested that a subset of CTCs (i.e., epithelial phenotype) as opposed to all CTCs had a poorer prognostic impact in PA patients ([@bib29]). To summarise, our results suggest that CTC detection may be useful for PA diagnosis, whereas their detection provides no relevant prognostic information.

We observed that CA19.9, which has been widely investigated in pancreatic illness ([@bib44]), was also the most relevant marker for PA diagnosis, with a sensitivity of 79% and specificity of 93%. Two meta-analyses found similar values, with 79--81% sensitivity and 82--90% specificity ([@bib3]; [@bib36]). However, the usefulness of CA19.9 for PA diagnosis is still debated because of its low specificity. This value is elevated in several conditions, including chronic pancreatitis or cholestasis. An increase in CA19.9 was described in 15--20% of chronic pancreatitis without associated-cholestasis or PA ([@bib28]; [@bib34]). Normal values in the presence of PA have also been reported in 5--10% of the population due to the lack of Lewis antigen expression. Because 63% of the PA patients in our work presented concomitant cholestasis at the initial EUS-FNA, the interpretation of the CA19.9 results needs to be taken with caution. Indeed, diagnosis values of CA19.9 were particularly interesting in patients without cholestasis (sensitivity and specificity of 81% and 100%, respectively), whereas the performance decreased in patients with cholestasis (sensitivity and specificity of 74% and 67%, respectively) ([Supplementary Tables 2 and 3](#sup1){ref-type="supplementary-material"}). To overcome this limitation, we analysed the CTC and ctDNA in combination with CA19.9. The results showed that the presence of at least two markers was associated with a sensitivity and specificity of 78% and 91%, respectively. In patients with cholestasis, the combination improved the diagnosis accuracy compared with CA19.9 alone (79% *vs* 73%, respectively) ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). Interestingly, the positive predictive value of the combination was 97% for PA compared with 93% for EUS-FNA. In light of these results, we believe that these circulating makers may be useful for diagnosing PA and that further studies are needed to evaluate the relevance of their detection alone and as a complement to EUS-FNA. Indeed, we showed that the association of EUS-FNA with CA19.9, which was the most efficient biomarker in our series, was associated with an increase in sensitivity (100%) but a loss of specificity (80%). The additional cost of EUS-FNA remains exorbitant compared with the cost for the analysis of all 3 biomarkers (i.e., \<\$300). Moreover, circulating approach could be performed the same day of the physician's visit.

The present study has some limitations. First, the patient cohort included few patients with benign lesions, which limits any definitive conclusions from these results, and additional larger studies are needed to confirm our results. The second limitation concerns the specificity of all three biomarkers, which have been reported to be associated with other solid tumours such as colon cancer. For example, increases in CA19.9 have been identified in gastric, colonic and esophageal adenocarcinoma at rates of 41%, 34% and 22%, respectively ([@bib35]). However, we analysed these markers in patients presenting an SPT. Pancreatic metastases represent a very rare etiology among SPT and occur in \<2% of all cases ([@bib17]; [@bib41]; [@bib40]). Considering that majority of these SPTs originate from renal carcinoma (which are exceptionally associated with increased CA19.9 expression or *KRAS* mutation ([@bib9]; [@bib37]; [@bib14]), we think that these markers are specific in the PA diagnosis for patients with SPTs. Another limitation concerns the preanalytical conditions (including the variable initial plasma volume), which may have affected the results of the cDNA analysis. Because of this important issue, we performed subsequent analyses showing that the plasma volume used for cDNA extraction did not appear to significantly influence the cDNA (total and tumour) results (see [Supplementary Figures 1--4](#sup1){ref-type="supplementary-material"}). Thus, prospective trials will be necessary to clarify the optimal preanalytical and analytical conditions used for the ctDNA and CTC analyses in these settings. Finally, we observed an EUS-FNA sensitivity of 73% in our population. This result is slightly inferior to previously reported results ([@bib12], [@bib13]; [@bib41]) and may be due in part to our EUS-FNA process, which was based on 3--4 fine needle passages, whereas several works reported better results using 5--7 passages ([@bib27]).

In conclusion, our results indicate that CA19.9 in combination with CTC and ctDNA analyses represents an interesting alternative for PA diagnosis in patients with SPTs. Indeed, if individual analyses of CTC or ctDNA do not appear to be superior to EUS-FNA for diagnosing PA, a combination of markers seems to be a more promising approach with higher sensitivity and specificity than EUS-FNA alone. We also found that ctDNA may reflect the tumour burden in patients with solid pancreatic tumours. These results need to be confirmed, and a prospective study is currently ongoing in our center (NCT02072616) to confirm the diagnostic and prognostic values of CA19.9, CTC and ctDNA in patients with PA.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
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![**Representation of circulating tumour DNA detection with ddPCR for two patients with pancreatic adenocarcinoma and a *KRAS* mutation (p.G12D for patient 47 and p.G12V for patient 63).** The graphs in (**A** and **C**) illustrate the data obtained with multiplex assays, and the graphs in (**B** and **D**) illustrate the data obtained with simplex assays. The blue and green dots represent droplets containing amplified mutant and wild-type alleles, respectively. The red dots correspond to droplets containing both mutant and wild-type alleles. The gray dots correspond to wells containing no alleles (no amplification). % circulating tumour DNA represents the fraction of mutant allele/total allele (wild-type allele+mutant allele). Abbreviation: ctDNA, circulating tumour DNA.](bjc2017250f1){#fig1}

![**Comparison of results obtained with the multiplex and simplex analyses.** The graph illustrates the concordance of the allelic frequency (*r*^2^=0.995) between the 23 samples that tested positive in the multiplex and simplex analyses.](bjc2017250f2){#fig2}

![**Overall survival of patients with pancreatic adenocarcinoma according to circulating biomarkers at baseline.** (**A**) Kaplan--Maier survival curve stratified by the presence (black line) or absence (red line) of CTCs. (**B**) Kaplan--Maier survival curve stratified by the CTC level above (black line) or below (red line) the median value (4 CTC ml^−1^). (**C**) Kaplan--Maier survival curve stratified by the presence (black line) or absence (red line) of ctDNA. (**D**) Kaplan--Maier survival curve stratified by the ctDNA level above (black line) or below (red line) the median allelic frequency value (0.75%). (**E**) Kaplan--Maier survival curve stratified by the cfDNA level above (black line) or below (red line) the median value (59.5 ng ml^−1^) expressed as ng ml^−1^ of plasma. (**F**) Kaplan--Maier survival curve stratified by the CA19.9 level above (black line) or below (red line) the median value (174 UI l^−1^).](bjc2017250f3){#fig3}

###### Patients characteristics

  **Characteristics**                                 **Total (** ***n*** **=68) n (%)**   **Adenocarcinoma (** ***n*** **=52) n (%)**   **ctDNA, (\<median)** [a](#t1-fn1){ref-type="fn"} **n**   **ctDNA, (⩾median)** [a](#t1-fn1){ref-type="fn"} **n**   ***P*** **value**
  -------------------------------------------------- ------------------------------------ --------------------------------------------- --------------------------------------------------------- -------------------------------------------------------- -------------------
  **Age at baseline (years)**                                                                                                                                                                                                                              
  Median (range)                                                 66 (18--89)                               67 (44--89)                                                                                                                                               
  \<Median                                                            34                                       26                                                   8                                                        13                                   0.22
  ⩾Median                                                             34                                       26                                                  13                                                        8                                       
  **Sex**                                                                                                                                                                                                                                                  
  Female                                                           29 (43)                                   23 (44)                                                7                                                        10                                   0.53
  Male                                                             39 (57)                                   29 (56)                                               14                                                        11                                      
  **Histological type**                                                                                                                                                                                                                                    
  Adenocarcinoma                                                   52 (76)                                  52 (100)                                               21                                                        22                                    \_
  Benign[b](#t1-fn2){ref-type="fn"}                                10 (15)                                     \_                                                  \_                                                        \_                                      
  Others[c](#t1-fn3){ref-type="fn"}                                 6 (9)                                      \_                                                  \_                                                        \_                                      
  **Tumour size (mm)**                                                                                                                                                                                                                                     
  Median (range)                                                30 (12.5--70)                             30 (12.5--67)                                                                                                                                              
  \<Median                                                            34                                       26                                                  13                                                        6                                    0.06
  ⩾Median                                                             34                                       26                                                   8                                                        15                                      
  Mean±s.d.                                                       33.5±12.9                                 34.3±11.8                                                                                                                                                
  **Tumour location**                                                                                                                                                                                                                                      
  Head                                                             48 (71)                                   35 (67)                                               16                                                        14                                   0.75
  Body                                                             16 (23)                                   13 (25)                                                4                                                        5                                       
  Tail                                                              4 (6)                                     4 (8)                                                 1                                                        2                                       
  **Stage of disease** [d](#t1-fn4){ref-type="fn"}                                                                                                                                                                                                         
  Resectable                                                       16 (28)                                   13 (25)                                                5                                                        3                                    0.45
  Locally Advanced                                                 18 (31)                                   17 (33)                                                8                                                        6                                       
  Metastasis                                                       24 (41)                                   22 (42)                                                8                                                        12                                      
  ***KRAS* mutational status**                                                                                                                                                                                                                             
  Mutant                                                              --                                     23 (72)                                                                                                                                                 
  Wild -Type                                                          --                                     9 (28)                                                NA                                                        NA                                    --
  Unknown                                                             --                                       20                                                                                                                                                    

Applicable for patients with pancreatic adenocarcinoma.

Includes nine chronic pancreatitis nodules and one pseudo-papillary tumour of pancreas.

Includes pancreatic neuroendocrine tumour (PanNET) (*n*=2), chronic myeloid leukaemia (*n*=1), B-cell lymphoid neoplasm (*n*=1), renal clear cell carcinoma (*n*=1), fibrolamellar hepatocellular carcinoma (*n*=1).

Applicable for PA and malignant non-PA tumours.

###### Overall accuracy of circulating biomarkers in comparison of EUS-FNA for the diagnosis of pancreatic adenocarcinoma

                              **Circulating biomarkers**                                                                                      
  --------------------------- ---------------------------- ------------- ------------- ------------- ---------------------------------------- --------------
  Sensitivity                 67% (33/49)                  65% (28/43)   79% (38/48)   78% (31/40)   73% (38/52)[b](#t2-fn3){ref-type="fn"}   100% (48/48)
  Specificity                 80% (12/15)                  75% (9/12)    93% (14/15)   91% (10/11)   88% (14/16)[c](#t2-fn4){ref-type="fn"}   80% (12/15)
  Positive predictive value   92% (33/36)                  90% (28/31)   97% (38/39)   97% (31/32)   93% (38/41)                              94% (48/51)
  Negative predictive value   43% (12/28)                  38% (9/24)    58% (14/24)   53% (10/19)   48% (13/27)                              100% (12/12)
  Accuracy                    70% (45/64)                  67% (37/55)   83% (52/63)   80% (41/51)   76% (52/68)                              95% (60/63)

Abbreviations: CTC=circulating tumour cells; ctDNA=circulating tumour DNA; EUS-FNA=Endoscopic ultrasound-guided fine needle aspiration.

The performance of EUS-FNA+CA19.9 combination was based on at least 1 positive result among EUS-FNA and CA19.9.

Suspicious for malignancy were counted as positive for malignancy.

Two false positive cases corresponded to clear-cell renal carcinoma and pancreatic neuroendocrine tumour (PanNET) for which the diagnosis will be adjusted retrospectively.

###### Results of KRAS detection in tumour tissue and plasma with multiplex analysis

                              ***KRAS*** **mutant (Tissue)**   ***KRAS*** **wild-type (Tissue)**   **Total (Tissue)**
  --------------------------- -------------------------------- ----------------------------------- --------------------
  *KRAS* mutant (Plasma)      14                               3                                   17
  *KRAS* wild-type (Plasma)   5                                5                                   10
  Total (Plasma)              19                               8                                   27

[^1]: These authors contributed equally to this work.
